Remicade (infliximab) - J&J
Taltz (ixekizumab) - Eli Lilly
Bimzelx (bimekizumab-bkzx) - UCB
Cimzia (certolizumab pegol) - Astellas, UCB
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
Cosentyx (secukinumab) - Novartis
Stelara (ustekinumab) - J&J
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Simponi (golimumab) - J&J
Orencia (abatacept) - BMS
apremilast - Generic mfg.
Enbrel (etanercept) - Pfizer, Amgen
https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQrj9zrXLZzRSMhDtKVxofnailxG8NbmY46rpw8KxkdF-0
 
Jessica Walsh1; Chao Li2; Xiaolan Ye2; Manish Patel2; Christopher D Saffore2; Sandra Ciecinski2; Martin Bergman3
 
May 23, 2026
 
Prev Next